Bone fractures and pathologic conditions like chronic wounds significantly reduce the quality of life for the patients, which is especially dramatic in an elderly population with considerable multi-morbidity and lead to substantial socio-economic costs. To improve the wound healing capacity of these patients, new strategies for the design of novel multi-functional biomaterials are required: they should be able to decrease extensive pathologic tissue degradation and specifically control angiogenesis in damaged vascularized tissues like bone and skin. Glycosaminoglycans (GAGs) like hyaluronan (HA) and chondroitin sulfate (CS) as important extracellular matrix (ECM) components are involved in several biological processes such as matrix remodeling and growth factor signaling, either by directly influencing the cellular response or by interacting with mediator proteins. This could be useful in functionalizing biomaterials, but native sulfated GAGs (sGAGs) show a high batch-to-batch variability and are limited in their availability. Chemically modified HA and CS derivatives with much more defined characteristics regarding their carbohydrate backbone, sulfate group distribution and sulfation degree are favorable to study the structure-function relationship of GAGs in their interaction with mediator proteins and/or cells and this might be used to precisely modulate activity profiles to stimulate wound healing. By combining collagen type I as the main structural protein of the bone and skin ECM with these GAG derivatives, 2.5-dimensional (2.5D) and 3D artificial ECM (aECM) coatings and hydrogels were developed. These biomaterials as well as the respective GAG derivatives alone were compared to native GAGs and used to analyze how the sulfation degree, pattern and carbohydrate backbone of GAGs influence: i) the activity of tissue inhibitor of metalloproteinase-3 (TIMP-3) and vascular endothelial growth factor-A (VEGF-A) as main regulators of ECM remodeling and angiogenesis, ii) the composition and characteristics of the developed 2.5D and 3D aECMs, iii) the enzymatic degradation of collagen-based aECMs and HA/collagen-based hydrogels, iv) the proliferation and functional morphology of endothelial cells. Surface plasmon resonance (SPR) and enzyme linked immunosorbent assay (ELISA) binding studies revealed that sulfated HA (sHA) derivatives interact with TIMP-3 and VEGF-A in a sulfation-dependent manner. sHA showed an enhanced interplay with these proteins compared to native GAGs like heparin (HEP) or CS, suggesting a further impact of the carbohydrate backbone and sulfation pattern. sGAGs alone were weak modulators of the matrix metalloproteinase-1 and -2 (MMP-1 and -2) activity and did not interfere with the inhibitory potential of TIMP-3 against these proteinases during enzyme kinetic analyses. However, the formation of TIMP 3/GAG complexes reduced the binding of TIMP-3 to cluster II and IV of its endocytic receptor low-density lipoprotein receptor-related protein-1 (LRP-1, mediates the up-take and degradation of TIMP-3 from the extracellular environment) in a sulfation- and GAG type-dependent manner. It is of note that the determined complex stabilities of TIMP-3 with cluster II and IV were almost identical indicating for the first time that both clusters contribute to the TIMP-3 binding. Competitive SPR experiments demonstrated that GAG polysaccharides interfere stronger with the TIMP 3/LRP-1 interplay than GAG oligosaccharides. The importance of the position of sulfation is highlighted by the finding that a sHA tetrasaccharide exclusively sulfated at the C6 position of the N-acetylglucosamine residues significantly blocked the receptor binding, while CS and HEP hexasaccharides had no detectable effects. Thus, sHA derivatives as part of biomaterials could be used to sequester and accumulate TIMP 3 in aECMs in a defined manner where sHA-bound TIMP-3 could decrease the matrix breakdown by potentially restoring the MMP/TIMP balance. GAG binding might extend the beneficial presence of TIMP-3 into wounds characterized by excessive pathologic tissue degradation (e.g. chronic wounds, osteoarthritis). Mediator protein interaction studies with sHA coated surfaces showed the simultaneous binding of TIMP-3 and VEGF-A, even though the sHA/VEGF-A interplay was preferred. Moreover, kinetic analysis revealed almost comparable affinities of both proteins for VEGF receptor-2 (VEGFR-2), explaining their competition that mainly regulates the activation of endothelial cells. Additional SPR measurements demonstrated that the binding of sGAGs to TIMP-3 or VEGF-A decreases the binding of the respective mediator protein to VEGFR-2. Likewise, a sulfation-dependent reduction of the binding signal was observed after pre-incubation of a mixture of TIMP-3 and VEGF-A with sGAG poly- and oligosaccharides. The biological consequences of GAGs interfering with VEGF-A/VEGFR-2 and TIMP-3/VEGFR 2 were assessed in vitro using porcine aortic endothelial cells stably transfected with VEGFR 2 (PAE/KDR cells). The presence of sHA both decreased VEGF-A activity and the activity of TIMP-3 to inhibit the VEGF-A-induced VEGFR-2 phosphorylation. The same decreased activities could be observed for the migration of endothelial cells. However, if sHA, TIMP-3 and VEGF-A were present simultaneously, sHA partially restored the TIMP-3-mediated blocking of VEGF-A activity. These findings provide novel insights into the regulatory potential of sHA during endothelial cell activation as an important aspect of angiogenesis, which could be translated into the design of biomaterials to treat abnormal angiogenesis. These sHA-containing materials might control the angiogenic response by modulating the activity of TIMP 3 and VEGF-A. The in vitro fibrillogenesis of collagen type I in the presence of sHA derivatives led to 2.5D collagen-based aECM coatings with stable collagen contents and GAG contents that resemble the organic part of the bone ECM. A burst release of GAGs was observed during the first hour of incubation in buffer with the GAG content remaining almost constant afterwards, implying that the number of GAG-binding sites of collagen restricts the amounts of associated GAGs. Moreover, two differently sulfated HA derivatives could for the first time be incorporated into one multi-GAG aECM as verified via agarose gel electrophoresis and fluorescence measurements. This illustrates the multiple options to modify the aECM composition and thereby potentially their functionality. Atomic force microscopy showed that the presence of sHA derivatives during fibrillogenesis significantly reduced the resulting fibril diameter in a concentration- and sulfation-dependent manner, indicating an interference of the GAGs with the self-assembly of collagen monomers. In line with enzyme kinetic results, none of the GAGs as part of aECMs altered the enzymatic collagen degradation via a bacterial collagenase. Thus aECMs were proven to be biodegradable independent from their composition, which is favorable concerning a potential biomedical usage of the aECMs e.g. as implant coatings. HA/collagen-based hydrogels containing fibrillar collagen embedded into a network of crosslinked HA and sGAGs were developed as 3D aECMs. Scanning electron microscopy demonstrated a porous structure of the gels after lyophilization, which could favor the cultivation of cells. The presence of collagen markedly enhanced the stability of the gels against the enzymatic degradation via hyaluronidase, something beneficial to clinical use as this is often limited by the generally fast breakdown of HA. Binding and release experiments with lysozyme, as positively charged model protein for e.g. pro-inflammatory cytokines, and VEGF A revealed that the sulfation of GAGs increased the protein binding capacity for pure GAG coatings and retarded the protein release from hydrogels compared to hydrogels without sGAGs. Moreover, the additional acrylation of sHA was shown to strongly reduce the interaction with both proteins when the primary hydroxyl groups were targets of acrylation. This stresses the influence of the substitution pattern on the protein binding properties of the GAG derivatives. However, hydrogel characteristics like the elastic modulus remained unaffected. The different interaction profiles of lysozyme and VEGF-A with GAGs demonstrated a protein-specific preference of different monosaccharide compositions, suggesting that the mediator protein binding could be simultaneously adjusted for several proteins by combining different GAG derivatives. This might allow the scavenging of pro-inflammatory cytokines and at the same time a binding and release of wound healing stimulating growth factors. Since there is a growing demand for biomaterials to regenerate injured vascularized tissues like bone and skin, endothelial cells were used to examine the direct effects of solute GAGs and hydrogels containing these GAGs in vitro. In both cases, sHA strongly enhanced the proliferation of PAE/KDR cells. A VEGFR-2-mediated effect of GAGs on endothelial cells as underlying mechanism is unlikely since GAGs alone did not bind to VEGFR-2 and had no influence on VEGFR-2 phosphorylation. Other factors like GAG-induced alterations of cell-matrix interactions and cell signaling could be responsible. In accordance with SPR results, a decreased endothelial cell proliferation stimulating activity of VEGF-A was observed in the presence of solute GAGs or after binding to hydrogels compared to the respective treatment without VEGF-A. However, tube formation could be observed in the presence of solute VEGF A and GAGs and within hydrogels with sGAGs that released sufficient VEGF-A amounts over time. Overall the presence of GAGs and VEGF-A strongly promoted the endothelial cell proliferation compared to the treatment with GAGs or VEGF-A alone. Thus, HA/collagen-based hydrogels functionalized with sHA derivatives offer a promising option for the design of “intelligent” biomaterials that direct and regulate the cellular behavior instead of simply acting as inert filling material. They could be used for the controlled delivery and/or scavenging of multiple mediator proteins, thus enhancing the local availability or reducing the activity of these GAG-interacting mediator proteins, or by directly influencing the cellular response. This might be applied to a range of pathological conditions by tuning the biomaterial compositions to patient-specific needs. However, extensive in vivo validation is required to show whether these in vitro findings could be used to control the biological activity of for instance TIMP-3 and VEGF-A, especially under the pathological conditions of extended matrix degradation and dysregulated angiogenesis.

Glycosaminoglycans (GAGs) play an important role in many biological processes in the extracellular matrix. In a theoretical approach, structures of monosaccharide building blocks of natural GAGs and their sulfated derivatives were optimized by a B3LYP6311ppdd//B3LYP/ 6-31+G(d) method. The dependence of the observed conformational properties on the applied methodology is described. NMR chemical shifts and proton-proton spin-spin coupling constants were calculated using the GIAO approach and analyzed in terms of the method's accuracy and sensitivity towards the influence of sulfation, O1-methylation, conformations of sugar ring, and ω dihedral angle. The net sulfation of the monosaccharides was found to be correlated with the 1H chemical shifts in the methyl group of the N-acetylated saccharides both theoretically and experimentally. The ω dihedral angle conformation populations of free monosaccharides and monosaccharide blocks within polymeric GAG molecules were calculated by a molecular dynamics approach using the GLYCAM06 force field and compared with the available NMR and quantum mechanical data. Qualitative trends for the impact of sulfation and ring conformation on the chemical shifts and proton-proton spin-spin coupling constants were obtained and discussed in terms of the potential and limitations of the computational methodology used to be complementary to NMR experiments and to assist in experimental data assignment.

Extracellular matrix (ECM) composition and structural integrity is one of many factors that influence cellular differentiation. Fibronectin (FN) which is in many tissues the most abundant ECM protein forms a unique fibrillary network. FN homes several binding sites for sulfated glycosaminoglycans (sGAG), such as heparin (Hep), which was previously shown to influence FN conformation and protein binding. Synthetically sulfated hyaluronan derivatives (sHA) can serve as model molecules with a well characterized sulfation pattern to study sGAG-FN interaction. Here is shown that the low-sulfated sHA (sHA1) interacts with FN and influences fibril assembly. The interaction of FN fibrils with sHA1 and Hep, but not with non-sulfated HA was visualized by immunofluorescent co-staining. FRET analysis of FN confirmed the presence of more extended fibrils in human bone marrow stromal cells (hBMSC)-derived ECM in response to sHA1 and Hep. Although both sHA1 and Hep affected FN conformation, exclusively sHA1 increased FN protein level and led to thinner fibrils. Further, only sHA1 had a pro-osteogenic effect and enhanced the activity of tissue non-specific alkaline phosphatase. We hypothesize that the sHA1-triggered change in FN assembly influences the entire ECM network and could be the underlying mechanism for the pro-osteogenic effect of sHA1 on hBMSC.

Bone fractures and pathologic conditions like chronic wounds significantly reduce the quality of life for the patients, which is especially dramatic in an elderly population with considerable multi-morbidity and lead to substantial socio-economic costs. To improve the wound healing capacity of these patients, new strategies for the design of novel multi-functional biomaterials are required: they should be able to decrease extensive pathologic tissue degradation and specifically control angiogenesis in damaged vascularized tissues like bone and skin. Glycosaminoglycans (GAGs) like hyaluronan (HA) and chondroitin sulfate (CS) as important extracellular matrix (ECM) components are involved in several biological processes such as matrix remodeling and growth factor signaling, either by directly influencing the cellular response or by interacting with mediator proteins. This could be useful in functionalizing biomaterials, but native sulfated GAGs (sGAGs) show a high batch-to-batch variability and are limited in their availability. Chemically modified HA and CS derivatives with much more defined characteristics regarding their carbohydrate backbone, sulfate group distribution and sulfation degree are favorable to study the structure-function relationship of GAGs in their interaction with mediator proteins and/or cells and this might be used to precisely modulate activity profiles to stimulate wound healing. By combining collagen type I as the main structural protein of the bone and skin ECM with these GAG derivatives, 2.5-dimensional (2.5D) and 3D artificial ECM (aECM) coatings and hydrogels were developed. These biomaterials as well as the respective GAG derivatives alone were compared to native GAGs and used to analyze how the sulfation degree, pattern and carbohydrate backbone of GAGs influence: i) the activity of tissue inhibitor of metalloproteinase-3 (TIMP-3) and vascular endothelial growth factor-A (VEGF-A) as main regulators of ECM remodeling and angiogenesis, ii) the composition and characteristics of the developed 2.5D and 3D aECMs, iii) the enzymatic degradation of collagen-based aECMs and HA/collagen-based hydrogels, iv) the proliferation and functional morphology of endothelial cells. Surface plasmon resonance (SPR) and enzyme linked immunosorbent assay (ELISA) binding studies revealed that sulfated HA (sHA) derivatives interact with TIMP-3 and VEGF-A in a sulfation-dependent manner. sHA showed an enhanced interplay with these proteins compared to native GAGs like heparin (HEP) or CS, suggesting a further impact of the carbohydrate backbone and sulfation pattern. sGAGs alone were weak modulators of the matrix metalloproteinase-1 and -2 (MMP-1 and -2) activity and did not interfere with the inhibitory potential of TIMP-3 against these proteinases during enzyme kinetic analyses. However, the formation of TIMP 3/GAG complexes reduced the binding of TIMP-3 to cluster II and IV of its endocytic receptor low-density lipoprotein receptor-related protein-1 (LRP-1, mediates the up-take and degradation of TIMP-3 from the extracellular environment) in a sulfation- and GAG type-dependent manner. It is of note that the determined complex stabilities of TIMP-3 with cluster II and IV were almost identical indicating for the first time that both clusters contribute to the TIMP-3 binding. Competitive SPR experiments demonstrated that GAG polysaccharides interfere stronger with the TIMP 3/LRP-1 interplay than GAG oligosaccharides. The importance of the position of sulfation is highlighted by the finding that a sHA tetrasaccharide exclusively sulfated at the C6 position of the N-acetylglucosamine residues significantly blocked the receptor binding, while CS and HEP hexasaccharides had no detectable effects. Thus, sHA derivatives as part of biomaterials could be used to sequester and accumulate TIMP 3 in aECMs in a defined manner where sHA-bound TIMP-3 could decrease the matrix breakdown by potentially restoring the MMP/TIMP balance. GAG binding might extend the beneficial presence of TIMP-3 into wounds characterized by excessive pathologic tissue degradation (e.g. chronic wounds, osteoarthritis). Mediator protein interaction studies with sHA coated surfaces showed the simultaneous binding of TIMP-3 and VEGF-A, even though the sHA/VEGF-A interplay was preferred. Moreover, kinetic analysis revealed almost comparable affinities of both proteins for VEGF receptor-2 (VEGFR-2), explaining their competition that mainly regulates the activation of endothelial cells. Additional SPR measurements demonstrated that the binding of sGAGs to TIMP-3 or VEGF-A decreases the binding of the respective mediator protein to VEGFR-2. Likewise, a sulfation-dependent reduction of the binding signal was observed after pre-incubation of a mixture of TIMP-3 and VEGF-A with sGAG poly- and oligosaccharides. The biological consequences of GAGs interfering with VEGF-A/VEGFR-2 and TIMP-3/VEGFR 2 were assessed in vitro using porcine aortic endothelial cells stably transfected with VEGFR 2 (PAE/KDR cells). The presence of sHA both decreased VEGF-A activity and the activity of TIMP-3 to inhibit the VEGF-A-induced VEGFR-2 phosphorylation. The same decreased activities could be observed for the migration of endothelial cells. However, if sHA, TIMP-3 and VEGF-A were present simultaneously, sHA partially restored the TIMP-3-mediated blocking of VEGF-A activity. These findings provide novel insights into the regulatory potential of sHA during endothelial cell activation as an important aspect of angiogenesis, which could be translated into the design of biomaterials to treat abnormal angiogenesis. These sHA-containing materials might control the angiogenic response by modulating the activity of TIMP 3 and VEGF-A. The in vitro fibrillogenesis of collagen type I in the presence of sHA derivatives led to 2.5D collagen-based aECM coatings with stable collagen contents and GAG contents that resemble the organic part of the bone ECM. A burst release of GAGs was observed during the first hour of incubation in buffer with the GAG content remaining almost constant afterwards, implying that the number of GAG-binding sites of collagen restricts the amounts of associated GAGs. Moreover, two differently sulfated HA derivatives could for the first time be incorporated into one multi-GAG aECM as verified via agarose gel electrophoresis and fluorescence measurements. This illustrates the multiple options to modify the aECM composition and thereby potentially their functionality. Atomic force microscopy showed that the presence of sHA derivatives during fibrillogenesis significantly reduced the resulting fibril diameter in a concentration- and sulfation-dependent manner, indicating an interference of the GAGs with the self-assembly of collagen monomers. In line with enzyme kinetic results, none of the GAGs as part of aECMs altered the enzymatic collagen degradation via a bacterial collagenase. Thus aECMs were proven to be biodegradable independent from their composition, which is favorable concerning a potential biomedical usage of the aECMs e.g. as implant coatings. HA/collagen-based hydrogels containing fibrillar collagen embedded into a network of crosslinked HA and sGAGs were developed as 3D aECMs. Scanning electron microscopy demonstrated a porous structure of the gels after lyophilization, which could favor the cultivation of cells. The presence of collagen markedly enhanced the stability of the gels against the enzymatic degradation via hyaluronidase, something beneficial to clinical use as this is often limited by the generally fast breakdown of HA. Binding and release experiments with lysozyme, as positively charged model protein for e.g. pro-inflammatory cytokines, and VEGF A revealed that the sulfation of GAGs increased the protein binding capacity for pure GAG coatings and retarded the protein release from hydrogels compared to hydrogels without sGAGs. Moreover, the additional acrylation of sHA was shown to strongly reduce the interaction with both proteins when the primary hydroxyl groups were targets of acrylation. This stresses the influence of the substitution pattern on the protein binding properties of the GAG derivatives. However, hydrogel characteristics like the elastic modulus remained unaffected. The different interaction profiles of lysozyme and VEGF-A with GAGs demonstrated a protein-specific preference of different monosaccharide compositions, suggesting that the mediator protein binding could be simultaneously adjusted for several proteins by combining different GAG derivatives. This might allow the scavenging of pro-inflammatory cytokines and at the same time a binding and release of wound healing stimulating growth factors. Since there is a growing demand for biomaterials to regenerate injured vascularized tissues like bone and skin, endothelial cells were used to examine the direct effects of solute GAGs and hydrogels containing these GAGs in vitro. In both cases, sHA strongly enhanced the proliferation of PAE/KDR cells. A VEGFR-2-mediated effect of GAGs on endothelial cells as underlying mechanism is unlikely since GAGs alone did not bind to VEGFR-2 and had no influence on VEGFR-2 phosphorylation. Other factors like GAG-induced alterations of cell-matrix interactions and cell signaling could be responsible. In accordance with SPR results, a decreased endothelial cell proliferation stimulating activity of VEGF-A was observed in the presence of solute GAGs or after binding to hydrogels compared to the respective treatment without VEGF-A. However, tube formation could be observed in the presence of solute VEGF A and GAGs and within hydrogels with sGAGs that released sufficient VEGF-A amounts over time. Overall the presence of GAGs and VEGF-A strongly promoted the endothelial cell proliferation compared to the treatment with GAGs or VEGF-A alone. Thus, HA/collagen-based hydrogels functionalized with sHA derivatives offer a promising option for the design of “intelligent” biomaterials that direct and regulate the cellular behavior instead of simply acting as inert filling material. They could be used for the controlled delivery and/or scavenging of multiple mediator proteins, thus enhancing the local availability or reducing the activity of these GAG-interacting mediator proteins, or by directly influencing the cellular response. This might be applied to a range of pathological conditions by tuning the biomaterial compositions to patient-specific needs. However, extensive in vivo validation is required to show whether these in vitro findings could be used to control the biological activity of for instance TIMP-3 and VEGF-A, especially under the pathological conditions of extended matrix degradation and dysregulated angiogenesis.

In drei inhaltlich abgeschlossen Teilen werden Fragestellungen bearbeitet, die sich mit dem Einsatz von Polyhydroxybutyraten als Scaffoldmaterialien für das Tissue Engioneering von Knochen beschäftigen. Zunächst wird ein Prozess optimiert, in dem mittels Verpressen und Auslösen von Platzhaltern (Porogen) poröse Träger (Scaffolds) aus Poly-3-hydroxybuttersäure (P3HB) sowie aus P3co4HB hergestellt werden. Diese Scaffolds werden in der Folge mechanisch und strukturell charakterisiert, wobei Druckfestigkeit, Dauerfestigkeit und Viskoelastizität untersucht werden. Im Ergebnis finden sich mehrere Kandidaten, die für die weitere Testung im Tierversuch in Frage kommen. Weiter wird das Abbauverhalten von schmelzgeponnenen P3HB-Fäden untersucht. Dabei wird ein beschleunigtes Modellsystem gewählt, das noch möglichst nahe am physiologischen Fall aber ohne biologisch aktive Komponente (zB. Enzyme) definiert wurde. Die Charakterisierung bedient sich hier der Gelpermeationschromatographie (GPC), des gasgestützten Elektronenrastermikroskops (ESEM), der differentiellen Thermoanalyse (DSC) und der Rasterkraftmikroskopie. Als Ergebnis zeichnete sich ab, dass neben der hydrolytischen Degradation im Gegensatz zu PHB mit kleinerer spezifischer Oberfläche bei den Fäden auch Erosion zum Abbau beiträgt. Eine partikuläre Freisetzung wird nicht beobachtet. Im dritten Teil werden textile Scaffolds aus P3HB mit einer künstlichen extrazellulären Matrix aus Chondroitinsulfaten (CS) und Kollagen versehen. Dem CS kann hier ein positiver Einfluss auf die osteogene Differenzierung von humanen mesenchymalen Stammzellen (hMSC) nachgewiesen werden. Dies wird zum einen durch die verstärkte Expression der alkalischen Phosphatase (ALP) sowie durch die Hochregulation von Proteinen ersichtlich, die bei der osteogenen Differenzierung essentiell sind. In wenigen Gene-Arrays lässt sich ebenfalls erkennen, dass die osteogene Differenzierung durch CS positiv beeinflusst wird. Insbesondere frühe Marker wie ZBTB16 und IGFBPs werden hier identifiziert. Basierend auf den Teilergebnissen wird am Ende ein Beitrag geliefert, der das Tissue Engineering insbesondere für überkritische Röhrenknochendefekte als Methode interessant erscheinen lässt. Dabei werden mechanische Lasten durch konventionelle Fixateure aufgenommen und der Defektraum durch den mehrfachen Einsatz von bio-funktionalisierten flachen Scaffolds gefüllt.:1. Vorwort 3 2. Allgemeine Einführung 5 2.1 Der Knochen 5 2.1.1 Die Knochenbildung 5 2.1.2 Zur Anatomie und Physiologie des Knochens 7 2.2 Tissue Engineering 11 2.2.1 Zelltypen für das Tissue Engineering von Knochen 12 2.2.2 Scaffold Design im Tissue Engineering von Knochen 13 2.3 Polyhydroxyalkanoate 13 2.4 Tissue Engineering am Röhrenknochen 16 2.4.1 Poly(3-hydroxybutyrat)-Scaffolds für das Tissue Engineering von Knochenersatz 17 2.4.2 Matrix Engineering 18 2.5 Ziel der Arbeit 19 3. Mechanik poröser PHB-Scaffolds 21 3.1 Einleitung 21 3.2 Materialien und Methoden 23 3.2.1 Polyhydroxybutyrate und Porogene 23 3.2.2 Uniaxiales Heißpressen 24 3.2.3 Mikrographie 26 3.2.4 Dynamische Differenzkalorimetrie (DSC) 26 3.2.5 Mechanische Druckversuche 26 3.2.6 Mikrocomputertomographie (μCT) 27 3.2.7 Zellviabilität auf den Scaffolds 28 3.3 Ergebnisse 29 3.3.1 Mikrographie 29 3.3.2 Mikrocomputertomographie (μCT) 33 3.3.3 Druckversuche 37 3.3.4 Dynamische Differenzkalorimetrie (DSC) 40 3.3.5 Zellviabilität 40 3.4 Diskussion 40 3.5 Schlussfolgernde Zusammenfassung 46 4. Degradation von P3HB-Fasern 47 4.1 Degradation von Polyhydroxyalkanoaten 47 4.2 Materialien und Methoden 49 4.2.1 Herstellung und Vorbehandlung textiler P3HB-Konstrukte 49 4.2.2 Mechanische Prüfung 50 4.2.3 Beschleunigte Degradation 50 4.2.4 Untersuchung der Oberfläche 50 4.2.5 Dynamische Differenzkalorimetrie (DSC) 51 4.2.6 Gel-Permeations-Chromatographie (GPC) 51 4.3 Ergebnisse 52 4.3.1 Mechanische Tests 52 4.3.2 Die Charakterisierung der Oberfläche 52 4.3.3 Thermische Fasereigenschaften.55 4.3.4 Untersuchung der Molekulargewichte in der GPC 58 4.4 Diskussion 60 4.5 Schlussfolgernde Zusammenfassung 64 5. hMSC auf textilen Scaffolds 67 5.1 Einleitung 67 5.2 Material und Methoden 68 5.2.1 Erzeugung der P3HB-Scaffolds 68 5.2.2 Die Immobilisierung der EZM-Komponenten auf den Scaffolds 69 5.2.3 Isolation, Vorkultur, Besiedlung und Kultur der humanen mesenchymalen Vorläuferzellen 69 5.2.4 Kombinierte Bestimmung von ALP, MTT und Proteingehalt 71 5.2.5 Mikroskopische Untersuchungen 72 5.2.6 Nachweis der Kalziummineralisierung 73 5.2.7 Quantitative real time reverse transcribing polymerase chain reaction (rt-PCR) 73 5.2.8 cRNA Microarray-Untersuchung 74 5.2.9 Zusätzliche Experimente 75 5.3 Ergebnisse 76 5.3.1 Vorhergehende Untersuchung 76 5.3.2 Rasterelektronen-Mikroskopie 77 5.3.3 Konfokale Laser-Scanning-Mikroskopie 79 5.3.4 ALP-Aktivität, SDH-Aktivität und Proteingehalt 82 5.3.5 Mineralisierende Kalziumabscheidung 86 5.3.6 rt-PCR 87 5.3.7 cRNA Microarray-Untersuchung 90 5.3.8 Kulturen von hMSC mit Chondroitinsulfat als gelöstem Zusatz 93 5.4 Diskussion 93 5.5 Schlussfolgernde Zusammenfassung 98 6. Zusammenfassung 101

Nonviral gene delivery, though limited by inefficiency, has extensive utility in cell therapy, tissue engineering, and diagnostics. Substrate-mediated gene delivery (SMD) increases efficiency and allows transfection at a cell-biomaterial interface, by immobilizing and concentrating nucleic acid complexes on a surface. Efficient SMD generally requires substrates to be coated with serum or other protein coatings to mediate nucleic acid complex immobilization, as well as cell adhesion and growth; however, this strategy limits reproducibility and may be difficult to translate for clinical applications. As an alternative, we screened a chemically defined combinatorial library of 20 different extracellular matrix mimetic substrates containing combinations of (1) different sulfated polysaccharides that are essential extracellular matrix glycosaminoglycans (GAGs), with (2) mimetic peptides derived from adhesion proteins, growth factors, and cell-penetrating domains, for use as SMD coatings. We identified optimal substrates for DNA lipoplex and polyplex SMD transfection of fibroblasts and human mesenchymal stem cells. Optimal extracellular matrix mimetic substrates varied between cell type, donor source, and transfection reagent, but typically contained Heparin GAG and an adhesion peptide. Multiple substrates significantly increased transgene expression (i.e. 2- to 20-fold) over standard protein coatings. Considering previous research of similar ligands, we hypothesize extracellular matrix mimetic substrates modulate cell adhesion, proliferation, and survival, as well as plasmid internalization and trafficking. Our results demonstrate the utility of screening combinatorial extracellular matrix mimetic substrates for optimal SMD transfection towards application- and patient-specific technologies.

Eine bevorzugte Zellquelle für den Einsatz im Tissue Engineering sind mesenchymale Stammzellen (MSZ). Diese besitzen, neben einer hohen Proliferationsrate, die Fähigkeit, sich in verschiedene Zellen des mesodermen Ursprungs und in die entsprechenden Gewebetypen zu entwickeln. Um ein funktionales Gewebe zu erhalten ist es Ziel, sich bereits in vitro den in vivo Bedingungen anzunähern. Hierbei spielen neben der dreidimensionalen Struktur der Scaffolds auch die biochemische Mikroumgebung der Zellen in Form der unlöslichen extrazellulären Matrix (EZM) und den löslichen Mediatorproteinen wie Wachstums- und Differenzierungsfaktoren, sowie die physikalische Stimulation der Zellen eine wichtige Rolle. Während sich gegenwärtige Untersuchungen im TE vorwiegend mit den alleinigen Einflussfaktoren beschäftigen, verfolgt die vorliegende Arbeit das Ziel, die Auswirkungen kombinierter Stimuli durch Verwendung einer artifiziellen EZM, bestehend aus definierten Komponenten der nativen EZM, und physikalischer Stimuli durch elektrische Felder zu untersuchen. Letzteres erfolgte mit einem innerhalb der Arbeitsgruppe neu entwickelten System, dass die Stimulation von Zellen mit ausschließlich elektrischen Feldern, ohne störende Nebeneinflüsse, erlaubt.

Collagen and glycosaminoglycans, such as hyaluronan and chondroitin sulfate, are the major components of bone extracellular matrix, and extracellular matrix composites are being evaluated for a wide range of clinical applications. The molecular and cellular effects of native and sulfatemodified glycosaminoglycans on osteocytes were investigated as critical regulators of bone remodeling. The effects of glycosaminoglycans on viability, necrosis, apoptosis, and regulation of gene expression were tested in two osteocyte-like cell lines, the murine MLO-Y4 and the rat UMR 106-01 cells. Glycosaminoglycans were non-toxic and incorporated by osteocytic cells. In MLO-Y4 cells, sulfation of glycosaminoglycans led to a significant inhibition of osteocyte apoptosis, 42% inhibition for highly sulfated chondroitin sulfate and 58% for highly sulfated hyaluronan, respectively. Cell proliferation was not affected. While treatment with highly sulfated chondroitin sulfate increased cell viability by 20% compared to the native chondroitin sulfate. In UMR 106- 01 cells, treatment with highly sulfated hyaluronan reduced the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio by 58% compared to the non-sulfated form, whereas highly sulfated chondroitin sulfate led to 60% reduction in the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio in comparison to the native chondroitin sulfate. The expression of SOST, the gene encoding sclerostin, was reduced by 50% and 45% by highly sulfated hyaluronan and chondroitin sulfate, respectively, compared to their native forms. The expression of BMP- 2, a marker of osteoblast differentiation, was doubled after treatment with the highly sulfated hyaluronan in comparison to its native form. In conclusion, highly sulfated glycosaminoglycans inhibit osteocyte apoptosis in vitro and promote an osteoblast-supporting gene expression profile.

Eine bevorzugte Zellquelle für den Einsatz im Tissue Engineering sind mesenchymale Stammzellen (MSZ). Diese besitzen, neben einer hohen Proliferationsrate, die Fähigkeit, sich in verschiedene Zellen des mesodermen Ursprungs und in die entsprechenden Gewebetypen zu entwickeln. Um ein funktionales Gewebe zu erhalten ist es Ziel, sich bereits in vitro den in vivo Bedingungen anzunähern. Hierbei spielen neben der dreidimensionalen Struktur der Scaffolds auch die biochemische Mikroumgebung der Zellen in Form der unlöslichen extrazellulären Matrix (EZM) und den löslichen Mediatorproteinen wie Wachstums- und Differenzierungsfaktoren, sowie die physikalische Stimulation der Zellen eine wichtige Rolle. Während sich gegenwärtige Untersuchungen im TE vorwiegend mit den alleinigen Einflussfaktoren beschäftigen, verfolgt die vorliegende Arbeit das Ziel, die Auswirkungen kombinierter Stimuli durch Verwendung einer artifiziellen EZM, bestehend aus definierten Komponenten der nativen EZM, und physikalischer Stimuli durch elektrische Felder zu untersuchen. Letzteres erfolgte mit einem innerhalb der Arbeitsgruppe neu entwickelten System, dass die Stimulation von Zellen mit ausschließlich elektrischen Feldern, ohne störende Nebeneinflüsse, erlaubt.:1 Einleitung und Zielstellung 2 Theoretische Grundlagen 2.1 Der Knochen 2.1.1 Allgemeine Biologie und Physiologie des Knochengewebes 2.1.2 Knochenersatzmaterialien 2.2 Tissue Engineering von Knochengewebe 2.2.1 Trägermaterialien für das TE von Knochen 2.2.2 Zellen für das TE von Knochen 2.2.3 Artifizielle extrazelluläre Matrizes für das TE von Knochen 2.3 Einfluss elektrischer Felder auf Knochenumbauprozesse 2.3.1 Methoden zur Applikation von elektrischen Feldern 2.3.2 In vitro Untersuchungen zum Einfluss elektrischer Felder 2.3.3 Methode der Transformator-ähnlichen Einkopplung (TC) 3 Materialien 3.1 Technische Hilfsmittel und Geräte 3.2 Verbrauchsmaterialien 3.3 Chemikalien, Reagenzien und Kits 3.4 Antikörper 3.5 Oligonukleotide 3.6 Puffer-, Medien- und Lösungszusammensetzungen 3.7 Zellen 4 Methoden 4.1 Polycaprolacton-Co-Lactid (PCL)-Scaffolds 4.1.1 Präparation und Hydrophilisierung der PCL-Scaffolds 4.1.2 Beschichtung der PCL-Scaffolds 4.1.3 Charakterisierung der Beschichtung auf den PCL-Scaffolds 4.2 Zellkulturtechniken 4.2.1 Auftauen und Subkultivierung 4.2.2 Einfrieren 4.2.3 Induktion der osteogenen Differenzierung 4.2.4 Induktion der adipogenen Differenzierung 4.2.5 Induktion der chondrogenen Differenzierung 4.2.6 Besiedlung und Kultivierung der Zell-Matrix-Konstrukte 4.2.7 Elektrische Stimulation der Zell-Matrix-Konstrukte 4.2.8 Blockierung definierter Signaltransduktionswege 4.3 Mikroskopische Analytik der Zellen 4.3.1 Darstellung der Zellverteilung mittels Rasterelektronenmikroskopie (REM) 4.3.2 Qualitative Bestimmung von Fetttröpfchen mittels Oil-Red-O Färbung 4.3.3 Qualitative Bestimmung der Mineralisierung mittels vonKossa- Färbung 4.4 Durchflusszytometrie 4.5 Biochemische Analytik der Zellen 4.5.1 Bestimmung der Zellzahl mittels Lactatdehydrogenase (LDH)- Aktivität 4.5.2 Bestimmung der alkalische Phosphatase (ALP)-Aktivität 4.5.3 Quantitative Bestimmung des Kalziumgehaltes 4.6 Molekularbiologische Analytik / Genexpressionsanalyse 4.6.1 RNA Extraktion 4.6.2 cDNA-Synthese / Reverse Transkriptase PCR (RT-PCR) 4.6.3 Amplifikation von cDNA mittels quantitativer Real-Time PCR (qPCR) 4.7 Statistische Auswertung 5 Weiterentwicklung der Kammer zur TC-Einkopplung 5.1 Grundlegende theoretische Betrachtungen zur TC-Einkopplung 5.1.1 Ersatzschaltbild der TC-Einkopplung 5.1.2 Abschätzung des Eisenkernquerschnitts 5.1.3 Einfluss der Primärwindungszahl 5.2 Neudimensionierung und Aufbau der Stimulationseinrichtung 5.3 Verlauf der elektrischen Größen 5.3.1 Simulation 5.3.2 Messung 5.3.3 Abschätzung des magnetischen Feldes in der Kammer 5.4 Zusammenfassung 6 Zellexperimentelle Ergebnisse 6.1 Charakterisierung der humanen MSZ nach in vitro Kultivierung 6.1.1 Morphologie 6.1.2 Phänotypische Charakterisierung mittels Durchflusszytometrie 6.1.3 Multipotentes Differenzierungspotential 6.2 Zellverhalten auf den unbeschichteten PCL-Scaffolds 6.2.1 Ermittlung eines geeigneten Besiedlungsregimes 6.2.2 Zellverteilung und Proliferation der MSZ 6.2.3 Osteogene Differenzierung der MSZ 6.3 Einfluss der aEZM auf das Zellverhalten von MSZ 6.3.1 Quantitative Bestimmung der aEZM-Komponenten 6.3.2 Einfluss der aEZM auf die Adhärenz und Proliferation von MSZ 6.3.3 Einfluss der aEZM auf die osteogene Differenzierung von MSZ 6.4 Einfluss elektrischer Felder auf das Zellverhalten von MSZ 6.4.1 Einfluss der elektrischen Felder auf die Proliferation und osteogene Differenzierung von MSZ 6.4.2 Einfluss elektrischer Felder in Kombination mit Koll/sHya enthaltenden aEZM auf die Proliferation und osteogene Differenzierung von MSZ 6.4.3 Untersuchungen zu möglichen Signaltransduktionswegen 7 Diskussion der Ergebnisse 7.1 Charakterisierung der humanen MSZ nach in vitro Kultivierung 7.2 Zellverhalten auf den unbeschichteten PCL-Scaffolds 7.3 Einfluss der aEZM auf das Zellverhalten von MSZ 7.4 Einfluss elektrischer Felder auf das Zellverhalten von MSZ 8 Zusammenfassung und Ausblick Literaturverzeichnis Danksagung Eigene Publikationen und Mitautorschaften A Zusatzinformationen für die quantitative RT-PCR A.1 Versuchsdesign der Genexpressionsanalysen A.2 Qualitätskontrolle der isolierten RNA